MicroRNA 155 (miR-155) is involved in immune and inflammatory diseases and is associated with liver fibrosis and steatohepatitis. However, the mechanisms involved in miR-155 regulation of liver injury are largely unknown. The role of miR-155 in acute liver injury was assessed in wild-type (WT), miR-155 2/2 , and miR-155 2/2 mice transplanted with WT bone marrow.
M icroRNAs (miRNAs) are small noncoding RNAs that act as posttranscriptional regulators of gene expression. Each miRNA frequently targets several genes, and each gene can be targeted by several miRNAs, making miRNAs important fine-tuning regulators of gene expression in physiological or disease conditions. (1, 2) miRNA expression is context-dependent, with a specific miRNA expression profile for every organ, cell type, and physiological situation. In the context of liver disease, a dysregulation of miRNA expression has been well described in liver tissue, being of pathophysiological relevance. (3) (4) (5) However, the expression and role of miRNAs in inflammatory cells in the context of liver damage are still largely unknown. miR-155 is ubiquitously expressed in several tissues and cell types. miR-155 participates in the correct development of immune cells such as B and T lymphocytes, dendritic cells, and macrophages by regulating their function and activation. (6) (7) (8) (9) (10) (11) In addition, miR-155 regulates oncogenic pathways in solid tumors and hematological malignancies. (12, 13) Importantly, miR-155 function is context-dependent. The interaction of miR-155 with its target gene suppressor of cytokine signaling 1 (SOCS1) determines immune responses such as regulatory T cell (Treg) competitive fitness and natural killer (NK) cell expansion. However, when miR-155 functions independently of SOCS1, it regulates cluster of differentiation 8-positive (CD8
1
) T-cell responses and T helper 17 differentiation. (14, 15) Other target genes of miR-155, such as SH2 domain-containing inositol 5-phosphatase 1 (SHIP1), are known to regulate T helper 17 and Treg development and function. (16, 17) In the context of liver diseases, miR-155 is expressed in hepatocytes, (18, 19) endothelial cells, (20) and inflammatory cells such as monocytes, NK cells, and macrophages. (19, 21) Moreover, miR-155 has been described to be up-regulated in liver tissue of patients with hepatitis C virus and alcoholic liver disease (4, 21, 22) and to mediate cellular growth and transforming growth factor-b-dependent epithelial to mesenchymal transition in liver carcinogenesis. (18) However, the role of miR-155 in liver diseases is still not well understood and may depend on disease context. While miR-155 has been shown to be involved in the progression of liver inflammation, steatosis, and fibrosis in experimental models of chronic alcoholic liver disease, (22) (23) (24) in a nonalcoholic steatohepatitis model miR-155 played a hepatoprotective role. (25) In the present study, miR-155 deficiency was found to enhance acute liver injury and promote an alteration of inflammatory cell recruitment. Interestingly, by restoring miR-155 expression in inflammatory cells in miR-155-deficient mice (miR-155 2/2 ) the phenotype was partially reversed, suggesting that miR-155 deficiency in immune cells may enhance liver injury. Similar to previous studies in mice, the expression of miR-155 in patients with liver disease was increased in liver tissue but decreased in circulating inflammatory cells. These results suggest that miR-155 expression in immune cells may play a role in liver injury and disease, and thus, restoration of miR-155 expression in inflammatory cells might be a strategy to modulate liver injury.
Patients and Methods

PATIENTS
Liver biopsies were obtained from a cohort of consecutive patients with clinical, analytical, and histological features of autoimmune hepatitis (AIH, n 5 15) and liver cirrhosis (alcoholic liver disease [n 5 16] or nonalcoholic steatohepatitis [n 5 3]). All patients were admitted to the Liver Unit of the Hospital Clinic of Barcelona from July 2009 to December 2016, and informed consent was obtained from all patients, according to the ethical guidelines of the 1975 Declaration of Helsinki; the study was approved by the Ethics Committee of the Hospital Clinic of Barcelona. The characteristics of patients with AIH from whom liver biopsies were obtained are shown in Supporting Table  S1 . Liver samples obtained from optimal cadaveric liver donors or resections of liver metastasis were used as controls. All controls had normal serum aminotransferase levels and normal histology, as described. (26) Peripheral blood mononuclear cells (PBMCs) were isolated from patients with AIH (Supporting Table  S2 ) and from patients with liver cirrhosis (Supporting Table S3 ).
ISOLATION OF PBMCs
PBMCs were isolated from peripheral blood samples using cell preparation tubes with sodium citrate and a density gradient liquid (Ficoll) following the manufacturer's instructions (BD, NJ). ) were obtained from Jackson Laboratories (Bar Harbor, ME). Congenic CD45.1 mice (B6.SJL-PtprcaPepcb/ BoyCrl) were purchased from Charles River Laboratories (l'Arbresle, France). As control wild-type (WT) mice, we used a C57BL/6J inbred strain as suggested by the provider of the miR-155-deficient animals. WT mice were housed and bred in the same animal facility and in the same conditions as miR-155 2/2 animals. WT, miR-155
, and CD45.1 mice share a C57BL/ 6J genetic background, including their major histocompatibility complex molecules.
ANIMAL MODELS
For concanavalin A (ConA) treatment, mice were injected intravenously with 10 mg/kg of ConA. Animals were sacrificed to perform analysis at 8 or 18 hours after the injection. Blood and liver samples were collected.
For acetaminophen (APAP) treatment, 12-weekold male mice were fasted overnight with free access to water. Afterward the mice were intraperitoneally injected with 500 mg/kg of APAP resuspended in warm saline (NaCl 0, 9%). Twenty-four hours after the injection, the animals were sacrificed and blood and liver samples collected.
To inhibit SHIP1 activity, the inhibitor 3AC (Millipore) was used (herein referred to as iSHIP). A solution of iSHIP was prepared in 0, 3% hydroxypropylcellulose in phosphate-buffered saline (w/v). Mice received, over 2 days, intraperitoneal injections of iSHIP at 26.5 mg/kg or vehicle. Twenty-four hours after the last iSHIP injection, ConA was administered intravenously at 10 mg/kg to all animals. After 18 hours, animals were sacrificed. Blood and liver samples were collected.
A 
STATISTICAL ANALYSIS
Values for the quantitative variables are expressed as mean 6 standard deviation. Comparisons between groups were performed using the Student t test.
Further experimental procedures are described in the Supporting Information.
Results
miR-155 DEFICIENCY ENHANCES ConA-INDUCED ACUTE LIVER INJURY
In order to determine the effect of miR-155 expression during liver injury, we evaluated the effect of ConA and APAP intoxication in miR-155 2/2 mice, two well-described acute liver injury models with different modes of action. ConA treatment induces acute liver injury mediated by T cells and is considered to be a good experimental model of AIH. (27, 28) ConA treatment induced a marked increase of miR-155 expression in liver tissue of WT mice, 20-fold more than vehicle-treated animals (Fig. 1A) . Next, we evaluated the effect of ConA in miR-155 2/2 mice. ConA treatment induced a significant increase in serum levels of liver aminotransferases (i.e., aspartate aminotransferase [AST], alanine aminotransferase [ALT], and lactate dehydrogenase [LDH]) in WT mice, which were substantially higher in miR-155-deficient animals at both 18 and 8 hours after ConA injection ( Fig. 1B;  Supporting Fig. S1A ). To evaluate liver damage, we performed a terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) assay, which stains apoptotic nuclei and necrotic areas. We observed that miR-155-deficient animals had an increase in liver necrosis compared to WT-treated animals ( We next explored whether cell death signaling was thus increased in miR-155 2/2 mice at 8 and 18 hours after ConA treatment. We observed that receptorinteracting serine/threonine-protein kinase 1 (RIPK1), RIPK3, cleaved caspase 3, and activation of c-Jun Nterminal kinase (JNK) were overexpressed in miR-155 2/2 livers compared with WT ConA-treated animals ( Fig. 1D; Supporting Fig. S1C ). These results suggested that lack of miR-155 increases apoptotic cell death. Furthermore, miR-155 2/2 ConA-treated animals showed increased gene expression of inflammatory mediators compared to WT animals, which was significant at 18 hours ( Fig. 1E; Supporting Fig.  S1D ). Animals deficient in miR-155 had a significant increase in liver expression of inflammatory mediators such as intercellular cell adhesion molecule 1, Il-12, as well as the CXC and CCL chemokine family members chemokine (C-X-C motif) ligand 1 (Cxcl1), Cxcl5, Cxcl9, Cxcl10, and Cxcl11 and chemokine (C-C motif) ligand 2 (Ccl2) compared to WT ConA-treated animals (Fig. 1E) . No changes were observed in the expression of other inflammatory mediators such as tumor necrosis factor-a, IL-1b, Il-6, Il-10, Nos2, Arg1, Mrc1, and Il-4 (Supporting Fig. S2B ).
On the other hand, APAP intoxication triggers hepatocyte death and release of danger-associated molecular patterns, thus promoting infiltration of macrophages and NK T cells. (29, 30) APAP did not induce miR-155 expression in WT compared to vehicletreated animals (Supporting Fig. S3A ). APAP administration in miR-155-deficient mice induced a nonsignificant increase in serum liver aminotransferases and LDH compared to APAP-treated WT mice (Supporting Fig. S3B ). Likewise, no major changes were observed in the liver histology and inflammatory cytokine expression (Supporting Fig. S3D ).
Overall these results suggest that the effect of miR-155 deficiency on liver injury may depend on the type of injury, being most important in T cell-mediated liver injury.
DEFICIENCY OF miR-155 ALTERS INFLAMMATORY CELL RECRUITMENT IN LIVER INJURY
Expression of miR-155 is important for inflammatory cell differentiation and recruitment.
(8) Therefore, we next evaluated the inflammatory cell populations recruited to the liver after ConA treatment in WT and miR-155-deficient mice. Staining of the panleukocyte marker CD45 and the neutrophil marker myeloperoxidase (MPO) showed a nonsignificant decrease in infiltrating inflammatory cells and neutrophils, respectively, in miR-155 2/2 mice compared to WT ConA-treated animals ( Fig. 2A) . Furthermore, flow-cytometric analysis showed that while recruitment of the total population of CD8 1 and CD4 1 cells did not change between the two groups after ConAinduced liver injury, CD4
1 chemokine (C-X-C motif) receptor 3-positive (CXCR3 1 ; tissue-homing T cells) was significantly decreased in miR-155 2/2 compared to WT ConA-treated mice ( Fig. 2B; Supporting Fig. S4) 1 cells produced less interferon-gamma (IFN-c), tumor necrosis factoralpha, and IL-5 than WT CD4 1 cells at 24 or 48 hours (Fig. 3A) . No differences were observed in the levels of IL-4, IL-2, and IL-10. Interestingly, CD4
1 splenocytes deficient in miR-155 showed a lower expression of Foxp3 (Fig. 3B) , reinforcing the idea that miR-155 expression is important in Treg differentiation. (31, 32) We further investigated the effect of miR-155 deficiency in Treg cells. First, we evaluated the number of Tregs in the spleen and those recruited to the liver. miR-155 2/2 animals had a significant decrease in CD4
1 Foxp3 1 cells in both the spleen and the liver (Fig. 3C) . Next, we evaluated miR-155 gene targets involved in Treg cell development such as Socs1 and Ship1. (14, 16, 17, 33) While Ship1 expression was found to be increased in CD4
1
CD25
1 Treg cells deficient in miR-155 compared to WT cells, no differences in Socs1 were observed (Fig. 3D) . In addition, expression of the anti-inflammatory cytokine Il-10 was lower compared to WT Treg cells.
Altogether, these results show that miR-155 deficiency induces an increase in Ship1 and a defective recruitment of Tregs to the liver, supporting former studies showing that miR-155 deficiency causes defective Treg development and function.
INHIBITION OF Ship1 ACTIVITY IN miR-155-DEFICIENT MICE
Ship1 is a well-known target gene of miR-155. (17) To evaluate the role of Ship1 in liver damage, we used 3AC (iSHIP), a selective inhibitor of SHIP1 polyphosphatase activity in WT and miR-155-deficient animals. As expected, ConA induced a higher level of liver aminotransferases in vehicle-treated miR-155 2/2 animals compared to WT. The increase in aminotransferase levels in miR-155 2/2 animals was blunted by iSHIP treatment; however, there were no significant changes in aminotransferase levels when compared to vehicle-treated miR-155 2/2 animals (Fig. 4A) . Moreover, Ship1 inhibition did not show changes in liver necrosis as assessed by TUNEL assay in miR-155-deficient or WT animals compared to vehicle-treated mice (Fig. 4B) . Altogether, Ship1 inhibition resulted in a trend toward decreased ALT, with no changes in necrosis. Next, we evaluated gene expression of several inflammatory mediators in the liver. Remarkably, we observed that Ship1 blockade in ConA-treated miR-155 2/2 animals decreased the expression of intercellular cell adhesion molecule 1, CCl2, Cxcl1, Cxcl5, and Cxcl10 with respect to vehicle-treated miR-155 2/2 animals (Fig. 4C ). As expected, iSHIP treatment restored the deficient recruitment of Foxp3 1 cells to the liver in animals deficient for miR-155. iSHIP-treated miR155 2/2 mice had a significant increase in Foxp3 recruitment when compared to vehicle-treated miR-155 2/2 animals (Fig. 4D) 1 CD25 1 Treg cells were isolated from WT (n 5 6) and miR-155 2/2 (n 5 6) mice and stimulated for 6 days. Gene expression of Socs1, Ship1, and Il-10 was analyzed by quantitative PCR. Significant P values are shown above the bars: *P < 0.05, **P < 0.01, ***P < 0.0001. Abbreviation: Tnfa, tumor necrosis factor-alpha. First, the liver expression of miR-155 in transplanted animals was assessed. The baseline liver expression of miR-155 in miR-155 2/2 WT BM mice was lower than in WT animals. Surprisingly, after ConA treatment, the miR-155 2/2 animals with WT BM showed a marked increase in miR-155 expression, which was higher than in WT animals (Supporting Fig. S5 ). This suggests that increased liver expression of miR-155 after ConA damage may be due to the expression of miR-155 in inflammatory cells.
WT BM transplantation into miR-155 2/2 mice reduced the serum levels of AST, ALT, and LDH when compared with miR-155 2/2 -miR-155
BM, although this was not significant (Fig. 5A) . Regarding liver histology, miR-155 2/2 mice receiving WT BM showed smaller necrotic areas compared with miR-155 2/2 mice transplanted with miR-155 2/2 BM (Fig. 5B) . However, recruitment of CD45 1 inflammatory cells and neutrophils (MPO staining) did not change between the two groups (Fig. 5B) . The reduction in liver necrosis observed in the WT BM-transplanted animals was confirmed by western blot with evaluation of the expression of several necrosis signaling proteins. We observed a marked reduction in the level of RIPK3, cleaved caspase-3, and phosphorylated JNK in the livers of miR-155 2/2 -WT BM, while RIPK1 did not change (Fig. 5C ). On the other hand, assessment of liver apoptosis by TUNEL assay showed a decreased positive staining in miR-155 2/2 mice transplanted with WT BM compared to miR-155 2/2 -miR-155
BM animals, but this difference was not statistically significant (Fig. 5D ). Nevertheless, a significant reduction was observed in the activity of caspases 3 and 7 in miR-155 2/2 mice transplanted with WT BM, suggesting that correct expression of miR-155 in inflammatory cells reduces apoptosis (Fig. 5E) . Notably, the gene expression level of several inflammatory mediators (i.e., intercellular cell adhesion molecule 1, Ccl2, Ccl20, Cxcl1, Cxcl5, Cxcl9, Cxcl10, Cxcl11, Ifn-c, and tumor necrosis factor-alpha) was reduced in miR-155 2/2 mice transplanted with WT BM compared to miR-155 2/2 -miR-155 2/2 BM (Fig. 5F ). Importantly, Foxp3 expression was increased in miR-155 2/2 WT BM mice, supporting the notion that Treg recruitment may be involved in the degree of liver injury. Overall, these results show that transplant of WT BM into miR-155 2/2 mice partially rescued their phenotype in acute liver injury and strongly suggest that miR-155 expression in inflammatory cells modulates liver inflammation and liver damage.
EXPRESSION OF miR-155 IN HUMAN SAMPLES
ConA treatment produces a liver injury similar to AIH and is frequently used as a mouse model of AIH. Therefore, we evaluated the expression of miR-155 in liver tissue and circulating PBMCs in patients with AIH as well as in patients with cirrhosis. Expression of miR-155 has been found increased in liver tissue of patients with cirrhosis compared to control livers (Fig.  6) . The increase was similar in compensated (3.37 6 3.48-fold) and decompensated (3.52 6 1.70-fold) patients. Notably, patients with AIH showed an important increase in miR-155 expression in liver tissue, with 7.6 6 5.6-fold compared to control livers and with a significant increase compared to patients with cirrhosis (Fig. 6A) . Experimental data from the ConA mouse model has suggested that a correct level of miR-155 expression in inflammatory cells may be important in modulating liver damage and inflammatory response; therefore, we evaluated the expression of miR-155 in PBMCs. Patients with AIH or with liver cirrhosis showed decreased expression of miR-155 in PBMCs compared to healthy controls (Fig. 6B) . No significant differences were observed between compensated and decompensated patients with cirrhosis (Fig.  6B) . On the other hand, we evaluated whether immunosuppressive treatment affected miR-155 expression in PBMCs of AIH patients. Our data show that AIH patients under immunosuppressive treatment and before treatment showed similar miR-155 expression levels in PBMCs (Fig. 6C) . Altogether these results suggest that changes in miR-155 expression in both liver and inflammatory cells occur in liver injury and diseases. 
Discussion
This study shows that the expression of miR-155 is altered in both liver tissue and inflammatory cells in liver injury and disease. With the use of miR-155-deficient mice, we found that miR-155 plays an important role in T lymphocyte-mediated liver injury, modulating the extent of liver injury, Treg cell recruitment, and cytokine production by T-helper cells. Interestingly, on restoration of miR-155 expression in inflammatory cells by WT BM transplantation in miR-155 2/2 animals, the extent of liver damage and cytokine expression was reduced. These results suggest that the expression of miR-155 in inflammatory cells may be important for the correct inflammatory response in liver disease.
miR-155 is expressed in most cell types and tissues, being implicated in a wide range of diseases. Therefore, understanding the role of miR-155 is challenging, particularly in multifactorial and/or complex conditions such as liver diseases. Recent studies have shown that miR-155 expression in liver tissue is increased in chronic liver disease and that it can be detected in the circulation. (4, 19, 22, 34) These studies suggest not only that miR-155 may play a role in the progression of liver diseases but also that it may be a potential biomarker. In a mouse model of chronic liver injury miR-155 deficiency was shown to mitigate liver inflammation and steatosis. (35) Although in our study the expression of miR-155 is protective in acute liver injury, these results are not necessarily contradictory because the role of miR-155 in acute or chronic conditions may be different due to a context-dependent role of miR-155. In addition, participation of cell types expressing miR-155 may change along the different phases of disease progression, and the expression of target genes may differ in the context of chronic or acute liver injury. Thus, therapeutic strategies aimed at modifying miR-155 expression should take into account miR-155 expression as well as its role along the different stages of liver disease.
To evaluate the role of miR-155 in liver injury, we evaluated the impact of miR-155 deficiency in two animal models of acute liver injury with different mechanisms of action. APAP-induced liver injury triggers death receptor-independent hepatocyte necrosis, which activates liver monocytes, thus attracting other inflammatory cells. (36) On the contrary, ConA treatment mainly induces an immune-mediated liver damage with a rapid recruitment of T lymphocytes to the liver triggered by activation of Kupffer cells, NK cells, and NK T cells, followed by hepatocyte death mediated by the activation of death receptors. (27, 37) Interestingly, while miR-155 2/2 mice treated with APAP did not show enhanced liver damage, miR-155 2/2 mice were more susceptible to ConA-induced liver injury (Fig.  F7  7) .These results are in agreement with previous reports suggesting that miR-155 may have an important role in inflammatory cell function and suggest the possible role of miR-155 expression in T lymphocytes for achieving correct inflammatory response. (6, 8, 38, 39) Independently of the direct or indirect effects of miR-155 on the regulation of ConA-induced inflammatory response, there is increasing evidence that miR-155 might play an important role in cell death. (40) Thus, we next investigated the mode of cell death during ConA administration. Interestingly, we observed increased expression of not only necrotic markers such as RIPK1 and RIPK3 but also caspase-3 cleavage. Thus, in keeping with the findings of previous studies, (40, 41) miR-155 might repress RIPK and cleaved caspase-3-dependent cell death. Furthermore, increased JNK activation was observed in miR-155-deficient livers, supporting a previous report suggesting that miR-155-inducing signals use the JNK pathway. (42) One of the main findings of the study is the reduced recruitment of CD4
1
CXCR3
1 cells in ConA-treated miR-155-deficient mice. The CXCR3 receptor is mainly expressed in T helper 1, but it is also expressed in tissue-homing Tregs. (43) In addition evaluation of Foxp3 1 cells in spleen and liver showed a reduced number in both tissues in miR-155 2/2 mice, suggesting that miR-155 deficiency decreases the number of total Tregs and the number of Tregs recruited to the liver. These results are in agreement with reports showing that Tregs are reduced in spleen and thymus of miR-155-deficient mice and suggest that miR-155 expression may be involved in the development and function of Treg cells. (31, 32) Moreover, we also showed reduced liver expression of Foxp3 in miR-155
2/2
ConA-treated mice, which is specifically expressed in Treg cells. Interestingly, WT BM transplant in miR-155 2/2 animals restored Foxp3 expression, further suggesting the role of miR-155 in maintaining the Treg population.
In order to evaluate if T-helper lymphocytes response may be altered by miR-155 expression, we isolated CD4 1 cells after ConA challenge and evaluated their cytokine profile. We observed a reduction in proinflammatory and anti-inflammatory cytokines and a reduction of Foxp3 gene expression. As previously described, IFNc production was reduced in CD4 1 miR-155-deficient cells, although no differences were observed in IFNc expression in whole-liver tissue of miR-155 2/2 mice. These results suggest that deficiency of miR-155 may alter not only T-helper recruitment but also the response to injury by regulating cytokine production in the context of liver injury. Nonetheless, these results do not imply that miR-155 posttranscriptionally regulates cytokine expression because the role of miR-155 in the regulation, maturation, and function of inflammatory cells, thus altering the CD4 1 cell inflammatory response, has been widely reported. (9, 32, 33, 44, 45) To further understand the phenotype of miR-155-deficient Treg cells, we isolated and cultured CD4 1
CD25
1 cells from WT and miR-155 2/2 mice. As expected, the target gene Ship1 was overexpressed in miR-155-deficient cells, while Il-10 was reduced. The inositol phosphatase Ship1 is largely known to be a regulator of the immune system, particularly in Treg cells. (16, 46, 47) The Ship1 inhibitor 3AC (iSHIP) has been described to promote a boost of the immune system and to improve the immunoregulatory capacity of cells. (48, 49) In order to understand the role of miR-155 and Ship1 in acute liver damage, we blocked Ship1 activity in miR-155 2/2 and WT mice. Our results show a reduction in the increase of liver aminotransferases of miR-155 2/2 mice treated with iSHIP compared to WT mice. Furthermore, iSHIP decreased the liver gene expression level of proinflammatory cytokines in miR-155 2/2 mice to a similar level as WT animals. As expected, the recruitment of Foxp3 1 cells was increased in iSHIP-treated miR-155 2/2 animals. Thus, we observed that the inhibition of Ship1 is able to inhibit the exacerbated inflammatory response observed in miR-155 2/2 ConA-treated mice (Fig. 7) .
To further elucidate if the expression of miR-155 in inflammatory cells may determine liver injury, we performed BM transplantation, which allowed evaluation of the role of miR-155 in the expression of inflammatory cells in liver injury. Although chimerism of engrafted WT BM was 72%, the effects were remarkable. Interestingly, there were no changes in global infiltration assessed by CD45, but cytokine expression was reduced in miR-155 2/2 WT BM mice, while the expression of Foxp3 was increased. Moreover, WT BM transplant into miR-155-deficient animals attenuated liver injury (Fig. 7) . These results suggest that miR-155 expression in inflammatory cells may play an important role in the modulation of liver injury and inflammatory response.
Our results do not exclude the possible role of miR-155 in liver parenchyma. On the contrary, we show that miR-155 is expressed in human and mouse liver tissue and that its expression increases in ConAderived acute liver injury and in acute and chronic liver diseases. This observation together with previous results suggest that miR-155 may have a pleiotropic role in the context of liver injury and disease and that correct expression in both liver tissue and inflammatory cells may be important. In an attempt to unveil the contribution of miR-155 expression in liver parenchyma to acute liver damage, we transplanted WT animals with miR-155-deficient BM. Unfortunately, miR-155-deficient BM cells showed poor engraftment with 50% of chimerism, thereby precluding its evaluation. Therefore, future studies are needed to elucidate the contribution of miR-155 expression in hepatocytes to acute liver injury.
Results in human samples indicate a dysregulation of miR-155 expression in both liver tissue and inflammatory cells in liver diseases. Interestingly, while the expression of miR-155 in human liver tissue is increased, a marked reduction in miR-155 expression was found in circulating PBMCs. Unfortunately, paired samples of liver tissue and PBMCs were not obtained; therefore, it cannot be excluded that changes of miR-155 expression in the liver tissue and in PBMCs may not be concomitant. Nevertheless, these results together with the experimental data suggest that in human diseases the expression of miR-155 in inflammatory cells is affected and may influence liver injury. Although the results obtained in humans clearly show significant changes in miR-155 expression, larger patient cohorts should be analyzed in order to assess the potential association of miR-155 expression with clinical parameters and disease outcome.
Overall, this study provides evidence that miR-155 is dysregulated in both liver tissue and inflammatory cells in a liver disease context. Moreover, our results suggest that correct expression of miR-155 in inflammatory cells may be critical for effective inflammatory response to injury, particularly in immune-mediated liver injury. These results highlight the importance of the regulation of miRNAs in different cell types and tissues in the context of liver diseases and suggest their importance in disease progression.
